Lactobacillus gasseri BNR17 Ameliorates Dexamethasone-Induced Muscle Loss in BALB/c Mice and C2C12 Myotubes
This study aimed to investigate the effects and mechanism of Lactobacillus gasseri BNR17, a probiotic strain isolated from human breast milk, on dexamethasone-induced muscle loss in mice and cultured myotubes. BALB/c mice were intraperitoneally injected with dexamethasone, and orally administered L. gasseri BNR17 for 21 days. L. gasseri BNR17 treatment ameliorated dexamethasone-induced decline in muscle function, as evidenced by an increase in forelimb grip strength, treadmill running time, and rotarod retention time in both female and male mice. In addition, L. gasseri BNR17 treatment significantly increased the mass of the gastrocnemius and quadriceps muscles. Dual-energy X-ray absorptiometry showed a significant increase in lean body mass and a decrease in fat mass in both whole body and hind limb after treatment with L. gasseri BNR17. It was found that L. gasseri BNR17 treatment downregulated serum myostatin level and the protein degradation pathway composed of muscle-specific ubiquitin E3 ligases, MuRF1 and MAFbx, and their transcription factor FoxO3. In contrast, L. gasseri BNR17 treatment upregulated serum insulin-like growth factor-1 level and Akt-mTOR-p70S6K signaling pathway involved in protein synthesis in muscle. As a result, L. gasseri BNR17 treatment significantly increased the levels of major muscular proteins such as myosin heavy chain and myoblast determination protein 1. Consistent with in vivo results, L. gasseri BNR17 culture supernatant significantly ameliorated dexamethasone-induced C2C12 myotube atrophy in vitro. In conclusion, L. gasseri BNR17 ameliorates muscle loss by downregulating the protein degradation pathway and upregulating the protein synthesis pathway.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Journal of medicinal food - (2024) vom: 04. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lee, Hyeon-Yeong [VerfasserIn] |
---|
Links: |
---|
Themen: |
BALB/c |
---|
Anmerkungen: |
Date Revised 04.04.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1089/jmf.2023.K.0278 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370637143 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370637143 | ||
003 | DE-627 | ||
005 | 20240405234435.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240405s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1089/jmf.2023.K.0278 |2 doi | |
028 | 5 | 2 | |a pubmed24n1366.xml |
035 | |a (DE-627)NLM370637143 | ||
035 | |a (NLM)38574296 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lee, Hyeon-Yeong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lactobacillus gasseri BNR17 Ameliorates Dexamethasone-Induced Muscle Loss in BALB/c Mice and C2C12 Myotubes |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 04.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a This study aimed to investigate the effects and mechanism of Lactobacillus gasseri BNR17, a probiotic strain isolated from human breast milk, on dexamethasone-induced muscle loss in mice and cultured myotubes. BALB/c mice were intraperitoneally injected with dexamethasone, and orally administered L. gasseri BNR17 for 21 days. L. gasseri BNR17 treatment ameliorated dexamethasone-induced decline in muscle function, as evidenced by an increase in forelimb grip strength, treadmill running time, and rotarod retention time in both female and male mice. In addition, L. gasseri BNR17 treatment significantly increased the mass of the gastrocnemius and quadriceps muscles. Dual-energy X-ray absorptiometry showed a significant increase in lean body mass and a decrease in fat mass in both whole body and hind limb after treatment with L. gasseri BNR17. It was found that L. gasseri BNR17 treatment downregulated serum myostatin level and the protein degradation pathway composed of muscle-specific ubiquitin E3 ligases, MuRF1 and MAFbx, and their transcription factor FoxO3. In contrast, L. gasseri BNR17 treatment upregulated serum insulin-like growth factor-1 level and Akt-mTOR-p70S6K signaling pathway involved in protein synthesis in muscle. As a result, L. gasseri BNR17 treatment significantly increased the levels of major muscular proteins such as myosin heavy chain and myoblast determination protein 1. Consistent with in vivo results, L. gasseri BNR17 culture supernatant significantly ameliorated dexamethasone-induced C2C12 myotube atrophy in vitro. In conclusion, L. gasseri BNR17 ameliorates muscle loss by downregulating the protein degradation pathway and upregulating the protein synthesis pathway | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a BALB/c | |
650 | 4 | |a C2C12 | |
650 | 4 | |a Lactobacillus gasseri BNR17 | |
650 | 4 | |a dexamethasone | |
650 | 4 | |a muscle loss | |
700 | 1 | |a Lee, Jongkyu |e verfasserin |4 aut | |
700 | 1 | |a Lim, Hyemi |e verfasserin |4 aut | |
700 | 1 | |a Kim, Hye-Young |e verfasserin |4 aut | |
700 | 1 | |a Koo, Yeon-Su |e verfasserin |4 aut | |
700 | 1 | |a Lim, Ji-Su |e verfasserin |4 aut | |
700 | 1 | |a Yoon, Yoosik |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medicinal food |d 1997 |g (2024) vom: 04. Apr. |w (DE-627)NLM097504017 |x 1557-7600 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:04 |g month:04 |
856 | 4 | 0 | |u http://dx.doi.org/10.1089/jmf.2023.K.0278 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 04 |c 04 |